October 22, 2025 Do GLP-1RAs Differ in Cardiometabolic Protection? Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes. Conexiant
October 20, 2025 FDA Okays First Oral GLP-1 for CV Risk Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke. Conexiant
October 20, 2025 Prevalent Oral HPV Infections Show Delayed Clearance, Study 3-country cohort measures oral HPV infection duration and clearance patterns in men. Conexiant
October 20, 2025 Which Hair Loss Treatments Truly Deliver Results? Researchers compare prescription and over-the-counter treatments for male hair loss to determine which best improve hair density. Conexiant
October 17, 2025 FDA Awards Nine CNPV Vouchers to Speed Reviews Pilot aims to expedite access to high‑impact therapies by streamlining FDA review and strengthening sponsor–agency collaboration. Conexiant
October 15, 2025 Medical Oddities: The Half-Hour Health Hack Metabolic tweaks, sensory sweet spots, antiviral spice, and a soothing cup for the heart and more this week. Conexiant
October 15, 2025 Study Describes Patterns in Reported Drug Interactions Researchers analyze about 177,000 drug interactions to identify key medication safety trends. Conexiant
October 14, 2025 Only 2% Screened: Closing the Male Gap “Men would like to believe they’re indestructible, so a fracture doesn’t have the implication that it should." KFF Health News
October 08, 2025 New Data Tie GLP-1 Therapies to GERD "These potential risks should be weighed against the established clinical benefits of this drug class." Conexiant